Dapagliflozin Trial for Breast Cancer Cardiotoxicity Reaches Primary Completion

A Phase 3 clinical trial (NCT06711185) investigating dapagliflozin 10 mg for myocardial remodeling in breast cancer patients treated with anthracycline-based chemotherapy reached primary completion on 2026-01-30. This milestone indicates that data collection for the primary outcome has concluded.

Background

Dapagliflozin is being studied for its potential to mitigate cardiotoxicity, specifically myocardial remodeling, in patients undergoing anthracycline-based chemotherapy for breast cancer. Anthracyclines are effective chemotherapy agents, but their use can be limited by cardiotoxicity, leading to conditions like heart failure. This trial aims to explore a preventative or ameliorative role for dapagliflozin in this context.

Trial design

The study, titled "Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy" (NCT06711185), is a Phase 3, prospective, randomized, double-blind, controlled clinical trial. It is designed to compare the effect of 9 months of treatment with dapagliflozin versus placebo. The trial enrolled 80 participants diagnosed with breast cancer. The intervention arm receives dapagliflozin 10 mg. The primary objective is to assess the effect on anthracycline-induced cardiotoxicity.

What this means

The primary completion of this Phase 3 trial signifies that all necessary data for the main outcome has been collected from the enrolled participants. The next steps involve comprehensive data analysis and the subsequent reporting of results. These findings will be crucial in determining whether dapagliflozin can offer a therapeutic benefit in managing or preventing anthracycline-induced cardiotoxicity in breast cancer patients, potentially addressing a significant unmet medical need in oncology.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06711185, titled "Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy," was posted on 2026-01-30 on clinicaltrials.gov.